STERIS (STE): the perfect score in medical sterilization
2026-07-07 · By Lubin Danilo, founder of Lubin Investment
STE: see the full analysis on Lubin Investment
STERIS supplies the equipment and services that sterilize medical instruments, preventing infections in hospitals and pharmaceutical plants. It passes all 10 criteria in my screener, with a stock trading at roughly 23 times its free cash flow.
Key takeaways
- STERIS passes all 10 criteria in my screener, a rare result I only see in a handful of companies.
- The company supplies the equipment and services that sterilize medical equipment, an invisible but essential business for any hospital.
- Free cash flow per share grows 28.1% a year on average over five years.
- The stock trades at roughly 23 times its free cash flow, a level that clearly recognizes its quality.
What STERIS does
STERIS supplies sterilization equipment (autoclaves, disinfection systems) and related services (maintenance, training, consumable chemicals) that let hospitals safely reuse surgical instruments, and pharmaceutical plants guarantee the sterility of their production lines. It's an invisible business to the general public, but absolutely essential: without reliable sterilization, surgery becomes a major infection risk.
The razor-blade model applied to healthcare
STERIS sells its sterilization equipment once, but the associated consumables (sterilization chemicals, spare parts, maintenance contracts) are purchased continuously over the equipment's entire lifespan, often a decade or more. This model generates recurring, predictable revenue well beyond the initial equipment sale.
Solid, profitable growth
STERIS shows a 13.2% net margin and a 17.9% cash return on invested capital. Free cash flow per share grows 28.1% a year on average over five years, a fast pace for an already well-established company in its sector. Share count declines slightly, a sign of net buybacks returning value to shareholders.
The moat: regulatory and operational trust
STERIS's moat rests on the trust built with hospitals and health regulators over decades: a hospital doesn't casually switch sterilization suppliers, since a failure in this area can cost lives. The regulatory certifications needed to operate in this sector also form a significant barrier to entry for a new competitor.
Valuation: a quality already recognized
At a P/FCF of roughly 23.3, STERIS trades at a level that clearly recognizes its quality, without being extreme. My reasonable buy price estimate even exceeds the current share price of $215.39, suggesting the market hasn't fully exhausted its recognition of this quality.
Risks to know
The main risk is exposure to hospital capital budgets, which can slow during periods of healthcare sector budget restrictions. One point of caution: sales growth, at 8.2% a year over 5 years, remains more modest than cash flow growth, worth watching over time.
What I take away from this
STERIS illustrates well an invisible but critical B2B business, with a solid recurring revenue model and rare financial quality. This isn't a bargain hiding in plain sight, but a company whose quality already seems fairly priced by the market, a profile I clearly prefer to a trendy company whose price leaves no room for error.
FAQ
What does STERIS do?
It supplies sterilization equipment (autoclaves, disinfection systems) and related services that let hospitals safely reuse surgical instruments.
Why does STERIS earn a perfect score?
It passes all 10 criteria in my screener: profitability, cash growth, controlled debt, expanding margins, and strong profit-to-cash conversion.
Is STERIS expensive on the stock market?
It trades at roughly 23 times its free cash flow, a level that recognizes its quality without being extreme.
What is the main risk with STERIS?
Exposure to hospital capital budgets, which can slow during periods of healthcare sector budget restrictions.
What protects STERIS from competition?
The trust built with hospitals and health regulators over decades, plus the regulatory certifications needed to operate in this sector.
STE: see the full analysis on Lubin Investment
About the author
Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).